

Michelle L Lifton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7314155/publications.pdf>

Version: 2024-02-01

21
papers

2,777
citations

643344

15
h-index

799663

21
g-index

24
all docs

24
docs citations

24
times ranked

6601
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. <i>Nature</i> , 2022, 603, 493-496.	13.7	326
2	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. <i>Cell</i> , 2022, 185, 1549-1555.e11.	13.5	59
3	A homologous or variant booster vaccine after Ad26.COVS immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, eabm4996.	5.8	13
4	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
5	Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center. <i>Npj Vaccines</i> , 2021, 6, 15.	2.9	5
6	Immunogenicity of Ad26.COVS vaccine against SARS-CoV-2 variants in humans. <i>Nature</i> , 2021, 596, 268-272.	13.7	290
7	Low-dose Ad26.COVS protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , 2021, 184, 3467-3473.e11.	13.5	49
8	The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. <i>Nature Immunology</i> , 2021, 22, 1294-1305.	7.0	20
9	Functional Perturbation of Mucosal Group 3 Innate Lymphoid and Natural Killer Cells in Simian-Human Immunodeficiency Virus/Simian Immunodeficiency Virus-Infected Infant Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	6
10	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020, 369, 812-817.	6.0	789
11	Strong T _H 1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	14
12	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. <i>Nature</i> , 2017, 543, 248-251.	13.7	699
13	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. <i>Molecular Therapy</i> , 2016, 24, 2021-2032.	3.7	41
14	Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw034.	0.4	15
15	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. <i>Journal of Virology</i> , 2015, 89, 6462-6480.	1.5	40
16	Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Vectors Prime for Strong Cellular Responses to Simian Immunodeficiency Virus Gag in Rhesus Macaques. <i>Vaccine Journal</i> , 2014, 21, 1385-1395.	3.2	13
17	Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 11088-11093.	3.3	58
18	An IL-2/Ig Fusion Protein Influences CD4+T Lymphocytes in Naive and Simian Immunodeficiency Virus-Infected Rhesus Monkeys. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 873-886.	0.5	20

#	ARTICLE	IF	CITATIONS
19	Simian immunodeficiency virus (SIV)â€™specific cytotoxic T lymphocytes in gastrointestinal tissues of chronically SIV-infected rhesus monkeys. <i>Blood</i> , 2001, 98, 3757-3761.	0.6	41
20	Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination. <i>Journal of Virology</i> , 2001, 75, 5151-5158.	1.5	186
21	Human Immunodeficiency Virus Type 1 Envelope Epitope-Specific CD4+ T Lymphocytes in Simian/Human Immunodeficiency Virus-Infected and Vaccinated Rhesus Monkeys Detected Using a Peptide-Major Histocompatibility Complex Class II Tetramer. <i>Journal of Virology</i> , 2000, 74, 8751-8756.	1.5	30